Premal Patel, M.D. - Lyell
bm-navigation: bm-t3-home-navigation
bm-pageheader: bm-t3-pageheader

Premal Patel, M.D.

CMO

Premal Patel, M.D.

Premal Patel is a physician-scientist with 15 years of experience in medical oncology drug development, thoughtfully combining clinical strategy with adept biomarker approaches. Most recently, Premal was the SVP, Head of Early Clinical Drug Development at Juno therapeutics where he led CART efforts in multiple myeloma (including JCARH125 first-in human clinical development) and all solid tumor CART & TCR efforts (including multiple academic collaborations). Prior to this, he was VP, Head Early Clinical Development and Translational Research at Pfizer, where he led the allogenic CART effort (e.g. UCART19 IND and first in human program), along with ~15 immuno-oncology assets including CD3 bispecific antibodies, OX-40 and PD-1 antibodies and small molecule inhibitors.

Prior to this, he spent over 7 years at Genentech, Research and Early Development leading clinical development for several agents, including: aPD-L1+Avastin in renal cell carcinoma and AKT inhibitor (ipatasertib) across indications from inception to successful proof-of-concept at end of Phase 2.

Premal received BS Pharmacy from Rutgers University; MD and PhD degrees at University of Washington. He completed internal medicine at University of Washington and adult medical oncology at Memorial Sloan Kettering Cancer Center, where he researched targeted therapies for renal cell carcinoma.